GlassScriptPhysician profile
Lawrence A Brzozowski
NPI 1255353306
$7,677.88
in general payments reported to CMS, 2019-2025
35 companies · $89.22 in 2025
The $89.22 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,683 · 2020: $473 · 2021: $1,756 · 2022: $1,520 · 2023: $887 · 2024: $270 · 2025: $89.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,246.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $2,046.14 | 2019-2025 | Mavenclad |
| Teva Pharmaceuticals USA, INC. | $935.37 | 2019-2021 | |
| Celgene Corporation | $720.47 | 2019-2023 | Zeposia |
| Biogen, INC. | $603.53 | 2019-2022 | |
| Genentech USA, INC. | $573.44 | 2019-2021 | |
| Amgen INC. | $408.19 | 2019-2021 | |
| Genzyme Corporation | $357.63 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $357.57 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $249.06 | 2019-2022 | |
| Acorda Therapeutics, INC | $222.38 | 2019 | |
| Allergan, INC. | $191.91 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $124.00 | 2022 | |
| Impel Pharmaceuticals INC. | $115.00 | 2022 | |
| Horizon Therapeutics Plc | $101.92 | 2021 | |
| Mdd US Operations, LLC | $101.15 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $80.31 | 2021 | |
| Supernus Pharmaceuticals, INC. | $66.00 | 2019-2020 | |
| Abbvie INC. | $58.65 | 2023 | Botox |
| Eisai INC. | $42.56 | 2019 | |
| Adamas Pharmaceuticals, INC. | $30.34 | 2019 | |
| Arbor Pharmaceuticals, INC. | $30.29 | 2019 | |
| Jazz Pharmaceuticals INC. | $28.66 | 2019 | |
| Amneal Pharmaceuticals LLC | $27.96 | 2019 | |
| Alexion Pharmaceuticals, INC. | $27.62 | 2019 | |
| Argenx US, INC. | $26.43 | 2022 | |
| Bausch Health US, LLC | $22.11 | 2019 | |
| Greenwich Biosciences, INC. | $21.53 | 2019 | |
| Promius Pharma LLC | $16.96 | 2019 | |
| Lundbeck LLC | $15.99 | 2019 | |
| Assertio Therapeutics, INC. | $14.51 | 2019 | |
| Neurocrine Biosciences, INC. | $13.73 | 2019 | |
| Lilly USA, LLC | $12.72 | 2019 | |
| Acadia Pharmaceuticals INC | $11.39 | 2019 | |
| Strongbridge US INC. | $11.20 | 2019 | |
| Akcea Therapeutics, INC. | $11.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Brzozowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.